First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today ...
How Iran Immigrant Maky Zanganeh Is Now A Self-Made Billionaire In US
Maky Zanganeh became a billionaire after shares of Summit Therapeutics, where she serves as co-CEO, soared following positive ...
From Iran to Icon: How Immigrant Maky Zanganeh Became a Self-Made Billionaire in the US
Maky Zanganeh, Co-CEO of Summit Therapeutics' owns 5% of the biopharmaceutical company and stock options. One of the 34 ...
Medindia15h
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine
The proposed Phase 2 trial will evaluate the efficacy of the vaccine administered in the neoadjuvant (before surgery) setting, in combination with chemotherapy and Keytruda (pembr ...
Anixa Biosciences, Inc.: Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine
Announces focus on therapeutic approach; resulting in a faster and more cost-effective path to approval SAN JOSE, Calif., Sept. 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Compan ...
Business Insider16h
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
In monotherapy, BT-001 induced tumor shrinkage in 2 of 6 injected lesions.In combination with KEYTRUDA® (pembrolizumab), partial responses were observed in 2 of 6 patients who failed previous ...